Imaging technology provider Verisante Technology has entered into an exclusive agreement to license the worldwide rights for a novel multispectral imaging cancer detection technology with the inventors, Haishan Zeng PhD, and Yasser Fawzy of the British Columbia Cancer Agency.
The multispectral imaging technology is protected by a pending patent. Verisante now has the field of use rights to detect skin cancer and oral cancer and the right of first refusal for all other cancers, the company noted.
During the past 11 months, Verisante has acquired the rights to a broad portfolio of more than 24 patents and pending patents for cancer detection, including white-light reflectance imaging, fluorescence imaging, rapid Raman spectroscopy, and rapid multispectral imaging.
"By combining different modalities, we can increase the sensitivity and specificity of our devices, and ensure the longevity of our product life cycle by continually introducing new technologies," CEO Thomas Braun stated in a press release.
The multispectral imaging technology has the potential to be a very low-cost solution for skin and oral cancer detection that may prove to be more suitable for the primary care physician or general dentist who may not have the patient base to justify the higher cost of other devices, he added.
